Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Short CommunicationDriver mutations in oncogenesisFull text | PDFYear: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_26_2020 |
24,867 | 2,532 | 27,399 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text | PDFYear: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_30_2020 |
17,364 | 2,197 | 19,561 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2023 |
15,525 | 1,140 | 16,665 |
NewsEditorial board tribute to Dr. Amit VermaFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December |
14,326 | 1,590 | 15,916 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_8_2022 |
11,728 | 3,895 | 15,623 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_15_2023 |
14,560 | 998 | 15,558 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2023 |
14,609 | 927 | 15,536 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_5_2022 |
10,842 | 4,536 | 15,378 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_17_2023 |
14,470 | 663 | 15,133 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2023 |
13,516 | 1,202 | 14,718 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_16_2021 |
13,198 | 1,390 | 14,588 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2021 |
13,061 | 1,374 | 14,435 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text | PDFYear: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2022 |
13,809 | 586 | 14,395 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text | PDFYear: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_27_2022 |
13,873 | 454 | 14,327 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_1_2022 |
10,949 | 3,332 | 14,281 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_29_2022 |
12,958 | 953 | 13,911 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_2_2022 |
10,478 | 3,391 | 13,869 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text | PDFYear: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_26_2021 |
9,691 | 3,651 | 13,342 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text | PDFYear: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2021 |
11,465 | 1,731 | 13,196 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text | PDFYear: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_14_2022 |
9,343 | 3,279 | 12,622 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_3_2022 |
8,268 | 4,339 | 12,607 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text | PDFYear: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_11_2023 |
11,989 | 534 | 12,523 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_11_2022 |
10,395 | 2,064 | 12,459 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2021 |
10,742 | 1,699 | 12,441 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text | PDFYear: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_21_2019 |
9,905 | 2,533 | 12,438 |
EditorialNanobytesFull text | PDFYear: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2019 |
6,112 | 6,288 | 12,400 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2021 |
10,263 | 1,878 | 12,141 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2021 |
10,712 | 1,325 | 12,037 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text | PDFYear: 2021, Volume: 6, Issue: 2, October DOI: 10.25259/IJMIO_05_2020_ER |
11,018 | 872 | 11,890 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text | PDFYear: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_16_2023 |
11,002 | 779 | 11,781 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_10_2021 |
9,927 | 1,830 | 11,757 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text | PDFYear: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_36_2020 |
9,477 | 2,276 | 11,753 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text | PDFYear: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2021 |
10,161 | 1,432 | 11,593 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text | PDFYear: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_2_2021 |
8,909 | 2,672 | 11,581 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text | PDFYear: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_2_2019 |
7,391 | 4,124 | 11,515 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text | PDFYear: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_15_2020 |
7,770 | 3,375 | 11,145 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text | PDFYear: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2021 |
9,173 | 1,866 | 11,039 |
Letter to EditorLetter to editorFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_10_2022 |
7,660 | 3,364 | 11,024 |
Case ReportMetastatic endometrial carcinoma responsive to pembrolizumabFull text | PDFYear: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2020 |
6,265 | 4,576 | 10,841 |
Review ArticleCell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biologyFull text | PDFYear: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2019 |
5,920 | 4,833 | 10,753 |
Review ArticleResistance to poly ADP-ribose polymerase inhibitors and its clinical implicationsFull text | PDFYear: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_12_2022 |
6,887 | 3,814 | 10,701 |
Original ArticleReal World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Teratiary Care Cancer Center in IndiaFull text | PDFYear: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_1_2019 |
5,020 | 5,538 | 10,558 |
Review ArticleImpact of 2013 ASCO/CAP guidelines on various HER2 reporting categories in breast cancer by fluorescent in-situ hybridization and Immunohistochemistry: A meta-analysis with systematic reviewFull text | PDFYear: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_17_2019 |
5,399 | 5,140 | 10,539 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text | PDFYear: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2020 |
8,340 | 2,152 | 10,492 |
Case ReportA rare case of Exon 19 deletion transforming to Exon 20 insertion in a case of adenocarcinoma of lungFull text | PDFYear: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2022 |
8,392 | 1,770 | 10,162 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text | PDFYear: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_19_2019 |
7,056 | 3,016 | 10,072 |
EditorialImmune checkpoint inhibitor – antiangiogenic drugs combination in treatment-naïve metastatic clear cell renal cell carcinoma: Why should immunotherapy have all the fun!Full text | PDFYear: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_23_2019 |
5,114 | 4,647 | 9,761 |
EditorialMolecular insights into tumor microenvironment and targeted therapiesFull text | PDFYear: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_28_2021 |
7,549 | 2,182 | 9,731 |
Position PaperPractical consensus recommendations – Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapyFull text | PDFYear: 2019, Volume: 4, Issue: 1, January-April DOI: 10.25259/IJMIO-6-2019 |
5,375 | 4,255 | 9,630 |
Original ArticleAdvanced lung cancer and molecular testing in the middle of coronavirus disease 2019 second wave in the South Asian association for regional cooperation regionFull text | PDFYear: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_15_2021 |
7,206 | 2,379 | 9,585 |